[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chemsex\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chemsex":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,67,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100632143","integrating-sexual-pleasure-into-harm-reduction-services-for-men-who-have-sex-with-men-and-transgender-persons-who-engage-in-chemsex-or-substance-use-in-thailand-100632143",false,"NCT07509853","Integrating Sexual Pleasure Into Harm Reduction Services for Men Who Have Sex With Men and Transgender Persons Who Engage in Chemsex or Substance Use in Thailand","PLEASURE","Inclusion Criteria:\n\n* MSM, transgender women, transgender men, or non-binary persons\n* Age ≥18 years\n* Engaged in chemsex or substance use within past 12 months\n* Able to provide informed consent\n\nExclusion Criteria:\n\n• Unable to communicate in Thai sufficiently to complete study procedures","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","INTERVENTIONAL",[23],"NA","The study evaluates the integration of a sexual pleasure-based approach into harm reduction services for MSM and transgender persons engaging in chemsex or substance use in Thailand, using the \"Pleasuremeter\" tool to improve sexual health and related outcomes.",[26,27,28,29,30],"HIV Prevention","Substance Use","Mental Health","Sexually Transmitted Infections (STIs)","Chemsex",[32],"PrEP, Harm reduction, Chemsex, Transgender, Sexual pleasure","RECRUITING","2026-04-02",{"date":36,"type":37},"2026-04-08","ACTUAL",{"date":39,"type":37},"2025-05-01",{"date":41,"type":20},"2028-05-01",{"name":43,"class":44},"Institute of HIV Research and Innovation Foundation, Thailand","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":45},"100632374","the-implementation-of-a-trans-tailored-harm-reduction-service-for-transgender-persons-in-relation-to-chemsex-and-substance-use-it-rex-100632374","NCT07512856","The Implementation of a Trans-tailored Harm Reduction Service for Transgender Persons in Relation to chemsEX and Substance Use (iT-REX)","Inclusion Criteria:\n\n* Self-identified transgender women, transgender men, or non-binary persons\n* Age ≥18 years\n* HIV-negative\n* Engaged in chemsex or substance use within past 12 months\n* Able to provide informed consent\n\nExclusion Criteria:\n\n• Inability to communicate in Thai sufficiently to complete study procedures",{"count":53,"type":20},140,[23],"This study evaluates a comprehensive transgender-tailored harm reduction service for transgender women, transgender men, and non-binary individuals engaging in chemsex or substance use in Thailand, focusing on PrEP uptake, HIV\u002FSTI outcomes, mental health, and socio-legal impacts.",[26,27,57,29,30],"Mental Health Disorders",[59],"PrEP, Harm reduction, Chemsex, Transgender",{"date":61,"type":37},"2026-04-06",{"date":63,"type":37},"2024-02-01",{"date":65,"type":20},"2028-02-01",{"name":43,"class":44},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":96,"locationsCount":45},"100563034","faisability-and-efficacity-of-the-reinforced-communautary-support-program-parc-on-the-complications-of-chemsex-100563034","NCT06610916","Faisability and Efficacity of the Reinforced Communautary Support Program (PARC) on the Complications of Chemsex","E-PARC","Inclusion Criteria:\n\n* MSM and\u002For non-binary individuals, trans men or women associated with gay sexual networks\n* Engaging in chemsex (as defined by the European Chemsex Forum and having consumed at least twice a cathinone and\u002For methamphetamine and\u002For GHB\u002FGBL)\n* Seeking care for chemsex\n* Referred to the PARC program with the goal of reducing or stopping consumption\n* Not opposed to data collection for this study\n* Uncontrolled somatic or psychiatric conditions\n\nExclusion Criteria:\n\n* Refusal to participate","99 Years",{"count":76,"type":20},60,[23],"The complications associated with chemsex concern infectious disease specialists, addiction specialists, and public authorities. Chemsex is defined among men who have sex with men (MSM) and trans and non-binary individuals participating in gay hookup networks due to their specific psychological, sexual, and social characteristics. The drugs used in France are cathinones (3MMC), GBL, and methamphetamine, administered orally, nasally, rectally, and intravenously (\\"\\"slam\\"\\").\n\nBuilding on change models and health education theories, the teams at 190 and Spot Beaumarchais (AIDES) have created, within their shared facilities, the Parcours d\\'Accompagnement Renforcé Communautaire (PARC), a multidisciplinary and community-based program providing comprehensive care for chemsex complications. The program aims to achieve clinical benefits:\n\n* Reducing addiction symptoms\n* Decreasing somatic, psychiatric, and social risks related to chemsex\n* Exploring and addressing the determinants of consumption and complications, especially psychological and psychiatric\n* Improving social connections\n* Maintaining life and professional goals\n* Perceiving or creating new types of connections between men\n* Resuming physical activity\n* Improving self-esteem\n* Finding a satisfying and fulfilling sexuality\n* Enhancing overall quality of life\n\nThe goal of this study is to ensure that the PARC program, as designed, reaches its target population, is feasible, sustainable, at an acceptable cost, and improves the conditions of the population accessing it throughout the course. Thus, in the medium term, this study will identify all success factors for deploying such a program and build a toolkit for its dissemination to other regions with similar issues but somewhat different contexts.\n\nThe primary objective is to evaluate the feasibility of the PARC program in terms of implementation by measuring patient adherence to the program.\n\nThe primary outcome measure is the rate of patients who completed the follow-up in the PARC program compared to the number of patients who started the PARC program (at least the inclusion visit) over 18 months. A patient is considered adherent if they have attended at least one of each type of workshop offered during the first month AND continued to attend at least 4 workshops and 2 consultations per month during months 2 and 3.\n\nThe secondary objectives are:\n\n1. To evaluate the feasibility of the PARC program in terms of implementation, using the RE-AIM methodology (Glasgow):\n\n   * Reach: Does the included patient population accurately represent the target population? Does patient loss represent the most vulnerable patients?\n   * Intermediate Effectiveness at 3 months: (self-administered questionnaires)\n   * Overall quality of life\n   * Addiction criteria\n   * Somatic complications\n   * Social life\n   * Sexual quality of life\n   * Adoption of the intervention by professionals: Do addiction networks, CeGIDD, CSAPA, and city doctors refer their patients to the PARC program?\n   * Implementation of the intervention: Has the program evolved from the beginning to the end of the study? Have there been adaptations?\n   * Maintenance or sustainability: Is the financial model of the program sustainable and does it ensure a return on investment by analyzing the cost of care?\n2. To identify contextual factors that are facilitators or barriers to optimal implementation and effectiveness. (qualitative analysis)\n\nThe expected sample size is 60 patients included over a period of 18 months. Each patient will be included for a duration of 6 months, and the study will last for 24 months.\n\nOnce included, participants will complete the initial self-questionnaire collecting baseline socio-demographic, clinical characteristics, and all intermediate effectiveness outcome criteria \\"\\"before\\"\\". Concurrently with their participation in the program, they will complete various intermediate effectiveness evaluation questionnaires (\\"\\"after\\"\\") at 3 months (end of PARC) and 6 months (Post-PARC). Healthcare professionals running the PARC program will also complete questionnaires related to implementation indicators throughout the patients\\' course (Adoption, Implementation, Maintenance).\n\nQualitative interviews will be conducted with patients and relevant healthcare professionals to explore barriers and drivers to the optimal deployment of the PARC program and to examine each of the Reach, Adoption, Implementation, Maintenance indicators through an organizational approach",[30,80,81,82],"Addiction","Infections","Sexual Disorder, Physiological",[84,85,86,87,88],"chemsex","MSM","addiction","sexual health","HIV","NOT_YET_RECRUITING","2024-09-20",{"date":92,"type":37},"2024-09-24",{"date":90,"type":20},{"date":95,"type":20},"2026-09-20",{"name":97,"class":44},"Assistance Publique - Hôpitaux de Paris",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":21,"phases":107,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":114,"leadSponsor":116,"locationsCount":45},"100511880","effectiveness-of-tdcs-on-reducing-craving-in-patients-practicing-chemsex-a-single-center-double-blind-randomized-controlled-pilot-trial-100511880","NCT05945199","Effectiveness of tDCS on Reducing Craving in Patients Practicing Chemsex: a Single-center, Double-blind, Randomized Controlled Pilot Trial","CHEMSTIM","Inclusion Criteria:\n\n* Patient who provides written consent\n* Patient aged ≥ 18 years\n* Patient motivated and willing to change chemsex behavior, assessed by examiner during screening and inclusion visits\n* Patient using at least one of the following psychoactive substances to modify sexual performance and\u002For experience:\n\n  * Cathinones, or methamphetamine, or MDMA, or cocaine, or ketamine, or GBL\u002FGHB\n  * ≥ 1 time per month over the past 6 months and\u002For ≥ 10 times over the past year\n\nExclusion Criteria:\n\n* Patient with a substance use disorder not involved in the practice of chemsex\n* Patient with a recent change (\\\u003C 1 month) in the prescription of a psychotropic treatment\n* Patient presenting an acute psychiatric condition requiring hospitalization and\u002For immediate modification of a psychotropic treatment\n* Patients with unstable or uncontrolled neuropsychiatric disease\n* Patients with a history of epileptic seizures\n* Patients with unexplained episodes of loss of consciousness, as this condition may be linked to cerebral alterations or epilepsy\n* Patients with advanced or decompensated somatic pathology, requiring hospitalization expected during study follow-up\n* Patients suffering from any serious life-threatening illness, such as congestive heart failure, chronic obstructive pulmonary disease or active neoplasia\n* Patients with implanted cerebral medical devices, implanted pacemakers, or any electrically, magnetically or mechanically activated implant.\n* Patients with cardiac, neural or drug implants\n* Patients with vascular clips or other electrically sensitive support systems in the brain\n* Patients with severe brain lesions\n* Patients with skin lesions at stimulation sites\n* Patients with skin problems such as dermatitis, psoriasis or eczema\n* Patients with severe or frequent headaches\n* Patients who have already benefited from tDCS sessions\n* Pregnant, parturient or breast-feeding women (pregnancy test)\n* Staff working in the addictology department of Dijon University Hospital\n* Patient participating in another clinical trial\n* Patient not affiliated to national health insurance\n* Patient unable to complete assessment scales\n* Patient under psychiatric care without consent or under legal protection (guardianship, curatorship)\n* Major incapable or unable to provide consent",{"count":106,"type":20},40,[23],"The aim of this research is to evaluate the efficacy of a new treatment for chemsex or \"chemical sex\", the use of psychoactive substances to modify sexual experience and performance. This treatment, called Transcranial direct current stimulation (tDCS) aims to modulate the cortical activity of brain areas involved in the desire to use psychoactive substances, or drugs, and the desire for uncontrolled sexual intercourse.\n\nThis treatment should therefore lead to a reduction in the craving for consumption of psychoactive substances and\u002For the practice of uncontrolled sexual activity.\n\nThe stakes of this new treatment are high, because chemsex exposes people to health risks for themselves and others. These risks include the risk of infection (skin infections, HIV infection, hepatitis viruses), psychological harms (anxiety attacks, depression, suicide risk), risk of addiction (addiction to the psychoactive product used, sex addiction), and toxicological harm (overdose, dangerous combination of psychoactive substances) or trauma (blows, trauma to the genitals or anorectal trauma).\n\nTo date, there is no proven therapeutic treatment for people wishing to reduce or stop chemsex.\n\n40 participants will be randomized into 2 groups:\n\n* 20 patients will receive active stimulation\n* 20 patients will receive sham stimulation\n\nThe total duration of the study for each patient will be 13 weeks: 1 week of stimulation and 12 weeks of follow-up.",[30],"2024-07-29",{"date":112,"type":37},"2024-07-30",{"date":110,"type":37},{"date":115,"type":20},"2026-08",{"name":117,"class":44},"Centre Hospitalier Universitaire Dijon"]